Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon

This article was originally published in The Gray Sheet

Executive Summary

Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.

You may also be interested in...



Drug-Coated Balloon For Urethral Strictures Debuts In Europe, Version For BPH Planned

Urotronic set to complete a $20m series C, bringing its total funding to $61m for the development of drug-eluting balloon-based urology products.

Medtronic, Bard In Close Race To First FDA-Approved Drug-Eluting Balloon

Medtronic says it reached the necessary trial enrollment to support PMA approval for its IN.PACT Admiral drug-eluting balloon catheter to treat atherosclerosis in the superficial femoral artery. On the same day, CR Bard said it was prepared to submit its final PMA module for its Lutonix drug-eluting balloon by year’s end.

Drug-Coated Balloons Fuel Multibillion-Dollar Hopes

With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT030831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel